Episurf Medical AB Series B
Episurf Medical AB (publ), a medical device company, designs and manufactures implants and surgical instruments in Germany, Sweden, rest of Europe, the United States, and internationally. It offers Episealer Knee for repairing focal cartilage and bone defects to reduce pain and increase mobility in the patient's knee joint; Episealer implant, which is designed to fit anatomy and size of the lesio… Read more
Episurf Medical AB Series B (0QUT) - Net Assets
Latest net assets as of September 2021: Skr120.80 Million SEK
Based on the latest financial reports, Episurf Medical AB Series B (0QUT) has net assets worth Skr120.80 Million SEK as of September 2021.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr134.60 Million) and total liabilities (Skr13.80 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr120.80 Million |
| % of Total Assets | 89.75% |
| Annual Growth Rate | 94.42% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 158.5 |
Episurf Medical AB Series B - Net Assets Trend (2018–2020)
This chart illustrates how Episurf Medical AB Series B's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Episurf Medical AB Series B (2018–2020)
The table below shows the annual net assets of Episurf Medical AB Series B from 2018 to 2020.
| Year | Net Assets | Change |
|---|---|---|
| 2020-12-31 | Skr169.50 Million | +309.42% |
| 2019-12-31 | Skr41.40 Million | -7.59% |
| 2018-12-31 | Skr44.80 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Episurf Medical AB Series B's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13110000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2020)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr66.70 Million | 39.35% |
| Other Components | Skr546.00 Million | 322.12% |
| Total Equity | Skr169.50 Million | 100.00% |
Episurf Medical AB Series B Competitors by Market Cap
The table below lists competitors of Episurf Medical AB Series B ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NR Instant Produce Public Company Limited
BK:NRF
|
$6.69 Million |
|
Helium Evolution Incorporated
PINK:HEEVF
|
$6.70 Million |
|
BEYOND FRAMES ENTMT AB
F:8WP
|
$6.70 Million |
|
BARKSDALE RES CORP.
F:2NZ
|
$6.70 Million |
|
Sampann Utpadan India Limited
NSE:SAMPANN
|
$6.68 Million |
|
Peraso Inc
NASDAQ:PRSO
|
$6.68 Million |
|
National Tyre & Wheel Limited
F:N37
|
$6.68 Million |
|
MOSTOSTAL Płock SA
WAR:MSP
|
$6.68 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Episurf Medical AB Series B's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2019 to 2020, total equity changed from 41,400,000 to 169,500,000, a change of 128,100,000 (309.4%).
- Net loss of 63,900,000 reduced equity.
- Share repurchases of 191,000,000 reduced equity.
- Other factors increased equity by 383,000,000.
Equity Change Factors (2019 to 2020)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-63.90 Million | -37.7% |
| Share Repurchases | Skr191.00 Million | -112.68% |
| Other Changes | Skr383.00 Million | +225.96% |
| Total Change | Skr- | 309.42% |
Book Value vs Market Value Analysis
This analysis compares Episurf Medical AB Series B's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Episurf Medical AB Series B utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -37.70%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -912.86%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.09x
- Recent ROE (-37.70%) is above the historical average (-111.77%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -129.02% | -1344.19% | 0.08x | 1.22x | Skr-62.28 Million |
| 2019 | -168.60% | -1292.59% | 0.09x | 1.39x | Skr-73.94 Million |
| 2020 | -37.70% | -912.86% | 0.04x | 1.09x | Skr-80.85 Million |
Industry Comparison
This section compares Episurf Medical AB Series B's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Episurf Medical AB Series B (0QUT) | Skr120.80 Million | -129.02% | 0.11x | $6.69 Million |
| Nyfosa AB (0A0K) | $2.92 Billion | 39.50% | 2.88x | $973.31 Million |
| High Templar Tech Limited (0A2T) | $12.52 Billion | 4.70% | 0.13x | $255.82 Million |
| Strategy Inc (0A7O) | $51.04 Billion | -7.54% | 0.21x | $40.17 Billion |
| NACON SASU (0A9N) | $67.54 Million | 15.85% | 1.20x | $7.64 Million |
| Antin Infrastructure Partners (0AA5) | $23.79 Million | 108.98% | 1.09x | $573.10 Million |
| Truecaller AB Series B (0AA7) | $1.41 Billion | 18.30% | 0.20x | $281.60 Million |
| Brockhaus Technologies AG (0AAW) | $254.92 Million | -6.23% | 1.68x | $74.40 Million |
| Hyloris Pharmaceuticals S.A. (0AB6) | $48.06 Million | -24.09% | 0.32x | $71.96 Million |
| Kalray S.A. (0ABT) | $28.43 Million | -41.56% | 0.67x | $33.84 Million |
| Webuild S.p.A. (0BJP) | $1.43 Billion | 10.29% | 7.14x | $1.13 Billion |